Envoy Medical, Inc. (COCHW) stock
COCHWNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31Also trades as COCH
$0.03−0.00 (-15.49%)
Close on Oct 30, 2026Market cap $511.80MP/E –Yield –
Envoy Medical r&d expenses
Research and development expenses are spending on new products and technology.
Envoy Medical's R&D Expenses for the twelve months ending Jun 30, 2026 was $14.03M, up 34.1% year over year. For fiscal 2025 it was $12.49M, up 22.7% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.49M | +22.7% |
| FY2024 | Dec 31, 2024 | $10.18M | +13.7% |
| FY2023 | Dec 31, 2023 | $8.96M | +80.0% |
| FY2022 | Dec 31, 2022 | $4.98M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.13M | +26.0% |
| Q1 FY2026 | Mar 31, 2026 | $3.64M | +32.5% |
| Q4 FY2025 | Dec 31, 2025 | $4.55M | +84.3% |
| Q3 FY2025 | Sep 30, 2025 | $2.70M | -2.1% |
| Q2 FY2025 | Jun 30, 2025 | $2.49M | -4.1% |
| Q1 FY2025 | Mar 31, 2025 | $2.75M | +16.4% |
| Q4 FY2024 | Dec 31, 2024 | $2.47M | -19.1% |
| Q3 FY2024 | Sep 30, 2024 | $2.76M | +49.0% |
| Q2 FY2024 | Jun 30, 2024 | $2.59M | +20.3% |
| Q1 FY2024 | Mar 31, 2024 | $2.36M | +22.5% |
| Q4 FY2023 | Dec 31, 2023 | $3.06M | +111.7% |
| Q3 FY2023 | Sep 30, 2023 | $1.85M | +97.9% |
| Q2 FY2023 | Jun 30, 2023 | $2.15M | – |
| Q1 FY2023 | Mar 31, 2023 | $1.93M | – |
| Q4 FY2022 | Dec 31, 2022 | $1.44M | – |
| Q3 FY2022 | Sep 30, 2022 | $935.00K | – |